- Home
- FNLC vs VNDA Comparison
FNLC vs VNDA Comparison
Compare FNLC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNLC
- VNDA
- Stock Information
- Founded
- FNLC 1864
- VNDA 2002
- Country
- FNLC United States
- VNDA United States
- Employees
- FNLC N/A
- VNDA N/A
- Industry
- FNLC Major Banks
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- FNLC Finance
- VNDA Health Care
- Exchange
- FNLC Nasdaq
- VNDA Nasdaq
- Market Cap
- FNLC 263.4M
- VNDA 261.7M
- IPO Year
- FNLC 1999
- VNDA 2006
- Fundamental
- Price
- FNLC $23.83
- VNDA $4.55
- Analyst Decision
- FNLC
- VNDA Strong Buy
- Analyst Count
- FNLC 0
- VNDA 3
- Target Price
- FNLC N/A
- VNDA $15.33
- AVG Volume (30 Days)
- FNLC 13.4K
- VNDA 362.5K
- Earning Date
- FNLC 07-23-2025
- VNDA 07-30-2025
- Dividend Yield
- FNLC 6.08%
- VNDA N/A
- EPS Growth
- FNLC 1.61
- VNDA N/A
- EPS
- FNLC 2.52
- VNDA N/A
- Revenue
- FNLC $82,116,000.00
- VNDA $201,351,000.00
- Revenue This Year
- FNLC N/A
- VNDA $16.86
- Revenue Next Year
- FNLC N/A
- VNDA $39.78
- P/E Ratio
- FNLC $9.39
- VNDA N/A
- Revenue Growth
- FNLC 5.28
- VNDA 13.37
- 52 Week Low
- FNLC $22.11
- VNDA $3.81
- 52 Week High
- FNLC $31.05
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- FNLC 45.24
- VNDA 53.76
- Support Level
- FNLC $23.41
- VNDA $4.49
- Resistance Level
- FNLC $24.28
- VNDA $4.63
- Average True Range (ATR)
- FNLC 0.54
- VNDA 0.14
- MACD
- FNLC -0.07
- VNDA 0.00
- Stochastic Oscillator
- FNLC 24.56
- VNDA 50.00
About FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.